COMP <GO>
ZEPP vs NVDA // RSI-14 & 200D SMA MOMENTUM
Zepp Health Corporation each representing sixteen (Class A) (NYSE) VS. NVIDIA Corporation (NASDAQ) • 15-METRIC TALLY: ZEPP 1
— NVDA 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: NVDA
LAST: $2.25 (-3.85%) • MKT CAP: $33.0M
rsi-technicals
11.4
LAST: $213.66 (-0.80%) • MKT CAP: $5.15T
rsi-technicals
51.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZEPP VS. NVDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZEPP | NVDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 38.30% | 74.67% | -36.37 | NVDA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.70% | 65.06% | -79.76 | NVDA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 23.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.58% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -11.30% | 65.21% | -76.51 | NVDA | /operating-margins <GO> |
| Net Profit Margin | -15.50% | 63.66% | -79.16 | NVDA | /net-margins <GO> |
| Revenue Growth (YoY) | 41.80% | 83.38% | -41.58 | NVDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.02% | -0.02 | NVDA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.33 | 19.52 | -19.19 | NVDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | ZEPP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 9.01% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 11.4 | 51.1 | -39.66 | NVDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 2.04 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $33.0M | $5.15T | -$5.15T | NVDA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZEPP REV | NVDA REV | ZEPP GROSS % | NVDA GROSS % | ZEPP FCF | NVDA FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $215.94B | — | 71.1% | — | $96.68B |
| FY 2025 | $258.9M | $130.50B | 38.3% | 75.0% | -$26.2M | $60.85B |
| FY 2024 | $182.6M | $60.92B | 38.5% | 72.7% | -$25.8M | $27.02B |
| FY 2023 | $352.9M | $26.97B | — | 56.9% | $42.6M | $3.81B |
| FY 2022 | — | $26.91B | — | 64.9% | — | $8.13B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZEPP // BETA —
NVDA // BETA 2.04